Stockreport

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength [Seeking Alpha]

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF GILD's HIV portfolio, led by Biktarvy and new launch Yeztugo, is expected to sustain growth with no major patent expiries until 2036. While oncology / immunology rema [Read more]